ARMEN GARO H 4
4 · AGENUS INC · Filed Mar 9, 2026
Research Summary
AI-generated summary of this filing
Agenus CEO Garo Armen Receives 4,994-Share Award
What Happened
Garo H. Armen — Chairman, Chief Executive Officer and Principal Financial Officer of Agenus Inc. (AGEN) — received 4,994 shares of common stock as compensation (an award/acquisition) on March 6, 2026. The shares were valued at $2.96 each (closing price on March 6), for a total reported value of $14,782. The grant represents salary paid in stock in lieu of cash and the shares were issued fully vested on the date of issuance.
Key Details
- Transaction date: March 6, 2026; Form 4 filed March 9, 2026 (timely filing).
- Instrument: Award/stock issuance as salary in lieu of cash (code A).
- Shares: 4,994 shares acquired at $2.96 per share; total ≈ $14,782. Reported amount represents the net shares for the pay period ending March 6, 2026.
- Vesting: Shares issued fully vested under the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan.
- Holdings: Shares are held in Dr. Armen’s IRA accounts. Filing does not list total shares owned after this transaction.
- Other notes: Dr. Armen serves as trustee and has investment authority for a GRAT holding 23,950 shares and is a general partner in Pixie Partners, which owns 5,000 shares; he disclaims beneficial ownership to the extent of his pecuniary interest.
Context
This was a compensation-related issuance (salary paid in stock), not an open-market purchase or sale. Such awards often reflect payroll elections or company compensation policy rather than a direct market signal; they are reported for transparency under Section 16.
Insider Transaction Report
- Award
Common Stock
[F1][F2]2026-03-06$2.96/sh+4,994$14,782→ 330,535 total
- 31,298(indirect: See Footnote)
Common Stock
[F3] - 28,950(indirect: See Footnote)
Common Stock
[F4]
Footnotes (4)
- [F1]At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending March 6, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.
- [F2]$2.96 is the closing price of our Common Stock on March 6, 2026, the last trading day for the payroll date for the pay period ending March 6, 2026.
- [F3]Shares are held in Dr. Armen's IRA accounts.
- [F4]Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT holder of 23,950 shares of our Common Stock. Dr. Armen is a general partner in Pixie Partners, a General Partnership ("Pixie"), which as of the date of this report owns 5,000 shares of our Common Stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Pixie and disclaims beneficial ownership to the extent of his pecuniary interest therein.